Non-renal excretion makes a difference:
no need for dose-adjustment when renal
function declines.

Renal excretion

TRAJENTA® is different from most of the other DPP4 inhibitors (DPP4i) because it is primarily excreted via a non-kidney route. That makes TRAJENTA® simple to use:1

Click on the DPP4i tab above to reveal the share of renal excretion in %

Trajenta 5%
  • No requirement for additional drug-related renal function monitoring1
  • No dose adjustment required in patients with renal impairment1

This means that when used appropriately, TRAJENTA® provides a simple way for patients to stay on a licensed dose of DPP4i, even as renal function declines.1-4 Real-world evidence has shown that a high proportion of patients being treated with DPP4i are at risk of being on unlicensed doses.2-4 Indeed, DPP4i doses are not always adjusted in accordance with guidelines or recommendations as renal function declines.2-4

DPP4i dosing chart

TRAJENTA®: The only approved DPP4i that does not require dose reduction based on renal function.1-5

Required DPP4i dose with declining renal function, as measured by CrCl1-5

real-world studies dosing

Real-world studies

Different studies have shown that a significant proportion of renally impaired patients receive an unlicensed DPP4i dose1,2

47% of DPP4i patients (excluding patients treated with TRAJENTA®) with moderate to severe chronic kidney disease were on an unlicensed dose according to claims data (n=380) in a US study *2
For your practice, it means:
  • 5mg once daily

    A simple way to keep your patients on a licensed dose (when TRAJENTA® is administered as appropriate: 5mg OD)3

  • Avoid cumbersome conversations

    May avoid cumbersome conversations around dose adjustment4

  • No additional monitoring

    No requirement for additional drug-related renal function monitoring3

*The objective of this retrospective database study was to describe real world patterns of DPP4i use and to assess concordance with PI recommended dosing among patients with T2D and moderate to severe chronic kidney disease (CKD) (Stage 3b-5; indicated by eGFR value <45 mL/min/1.73m²) treated with sitagliptin, saxagliptin, or linagliptin. The study used Quintiles’ electronic medical records (Q-EMR) linked to administrative claims from Truven’s MarketScan database 2010-2014 in the US; 492 DPP4i patients with moderate to severe CKD were identified (323 on sitagliptin, 57 on saxagliptin, 112 on linagliptin).

CKD: Chronic Kidney Disease; eGFR: estimated Glomerular Filtration Rate; ESRD: End-Stage Renal Disease; OD: Once Daily; RI: Renal Impairment.

Hear what experts are saying about TRAJENTA® simplicity in dosing